Lotus Pharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (USFDA) has granted the final approval for the Company's Abbreviated New Drug Application (ANDA) for Lenalidomide Capsules, 2.5 mg and 20 mg, generic version of BMS/Celgene Corporation's Revlimid. Lotus has received the final approval for all strengths of Lenalidomide Capsules. Lotus/Alvogen expects to launch the product as per its settlement agreement with the originator in the US.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
286.5 TWD | -1.72% | +1.24% | +5.33% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.33% | 2.34B | |
+37.78% | 723B | |
+30.64% | 598B | |
-3.51% | 364B | |
+19.94% | 331B | |
+5.14% | 288B | |
+16.06% | 244B | |
-5.03% | 208B | |
+9.84% | 210B | |
+9.32% | 169B |
- Stock Market
- Equities
- 1795 Stock
- News Lotus Pharmaceutical Co., Ltd.
- Lotus Pharmaceutical Co., Ltd. Receives Final Approval for its ANDA for Lenalidomide Capsules, 2.5 Mg and 20 Mg from US FDA